Article
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2013
Zhukova Nataliya, Ramaswamy Vijay, Remke Marc, Pfaff Elke, Shih David J H, Martin Dianna C, Castelo-Branco Pedro, Baskin Berivan, Ray Peter N, Bouffet Eric, von Bueren André O, Jones David T W, Northcott Paul A, Kool Marcel, Sturm Dominik, Pugh Trevor J, Pomeroy Scott L, Cho Yoon-Jae, Pietsch Torsten, Gessi Marco, Rutkowski Stefan, Bognar Laszlo, Klekner Almos, Cho Byung-Kyu, Kim Seung-Ki, Wang Kyu-Chang, Eberhart Charles G, Fevre-Montange Michelle, Fouladi Maryam, French Pim J, Kros Max, Grajkowska Wieslawa A, Gupta Nalin, Weiss William A, Hauser Peter, Jabado Nada, Jouvet Anne, Jung Shin, Kumabe Toshihiro, Lach Boleslaw, Leonard Jeffrey R, Rubin Joshua B, Liau Linda M, Massimi Luca, Pollack Ian F, Shin Ra Young, Van Meir Erwin G, Zitterbart Karel, Schüller Ulrich, Hill Rebecca M, Lindsey Janet C, Schwalbe Ed C, Bailey Simon, Ellison David W, Hawkins Cynthia, Malkin David, Clifford Steven C, Korshunov Andrey, Pfister Stefan, Taylor Michael D, Tabori Uri
Abstract excerpt
PURPOSE: Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through the inclusion of molecular subgroup profiles. PATIENTS AND METHODS: We determined subgroup affiliation, TP53 mutation status, and clinical outcome in a discovery cohort of 397 medulloblastomas. We subsequently validated our results on an independent cohort of 156...
Read the complete abstract on PubMed